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Complete spontaneous regression of an
extrahepatic portal vein aneurysm
Purandath Lall, MBBS,a,b Lohith Potineni, MD,b and Hasan H. Dosluoglu, MD,a,b Buffalo, NY
Primary portal venous aneurysms are rare; however, they are the most common visceral venous aneurysms, and their
pathogenesis is not fully understood. Complications include thrombosis, rupture, and mass effect on adjacent structures.
The optimal management of these patients is not known. We describe a patient whose large (6-cm) portal vein aneurysm
underwent complete spontaneous regression over several years of serial observation. To our knowledge, this observation
has not been reported in the English literature. ( J Vasc Surg 2011;53:206-8.)Primary extrahepatic portomesenteric venous aneu-
rysms (PVAs) are rare. The first PVA was reported in 1956
on autopsy in a 21-year-old woman with cirrhosis by Bar-
zilai and Kleckner.1 Since then 200 cases have been
reported in the English literature, with most of these diag-
nosed incidentally on noninvasive abdominal imaging.2
Their etiology, pathophysiology, and natural history are
relatively unclear at this time. Symptomatic patients and
those with complications of thrombosis, rupture, and com-
pressive effects usually undergo surgical intervention. Pro-
phylactic repair of large asymptomatic PVAs has been rec-
ommended for good-risk patients3; however, the optimal
management of these asymptomatic venous aneurysms re-
mains unknown.
CASE REPORT
A 57-year-old man was referred to our vascular clinic with an
incidental finding of an asymptomatic 6-cm PVA on computed
tomography (CT) scanning in 2002. Six years earlier he had
suffered a bout of acute alcoholic pancreatitis and an abdominal
ultrasound at that time demonstrated a 5-cm portal vein aneurysm;
this prompted cessation of alcohol consumption.
At presentation, the patient denied abdominal pain, jaundice,
nausea, vomiting, or weight loss, and had no family history of liver
disease. Comorbidities included type II diabetes mellitus, hyper-
tension, hyperlipidemia, chronic obstructive pulmonary disease,
aortic valve insufficiency, and nonischemic alcoholic cardiomyop-
athy, with a left ventricular ejection fraction of 25% to 30%. The
physical examination was unremarkable, with no stigmata of
chronic hepatic disease or portal hypertension. He had no organo-
megaly on palpation or abdominal bruits. Results of laboratory
investigations, including liver function tests and hepatitis profile,
were within normal reference ranges at the initial assessment and
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206remained so throughout the follow-up period. The CT scan
showed the saccular, 6-cm extrahepatic PVA with no intramural
thrombus and no fatty infiltration of the liver; the spleen and
pancreas were unremarkable (Fig 1).
Because he was asymptomatic and medically high risk, we
elected for serial observation and aspirin therapy. During 5 years
(2002 to 2007) of follow-up, he remained asymptomatic, his
overall medical status was stable, but he was diagnosed with
hyperlipidemia and was prescribed simvastatin in 2006. There was
no change in weight, cardiac function (evidenced by echocardio-
gram showing 25% to 30% ejection fraction in 2007 and 2009), or
liver function. The PVA remained stable and did not undergo any
change in size on annual CT scanning.
Unknown to us, he was reported by our gastroenterology
colleagues as a large (6-cm) stable asymptomatic PVA in 2007.4
Our follow-up CT imaging that same year showed the maximal
diameter of the PVA was now 4.7 cm. Another follow-up CT scan
1 year later revealed complete regression of the PVA, with the
portal vein now measuring 1.6 cm at its greatest diameter (Fig 2),
and it has remained unchanged over the last 2 years of follow-up
(2008 to 2010).
DISCUSSION
The portal vein is formed by the junction of the supe-
rior mesenteric and splenic veins anterior to the inferior
vena cava and posterior to the neck of the pancreas, at the
level of the second lumbar vertebra.5 In adults, it measures
about 8 cm in length, but its diameter ranges from 0.6 to
1.2 cm on autopsy and up to 1.9 cm on ultrasound imag-
ing.4 There is general agreement that when its diameter
reaches or exceeds 2 cm, it is considered aneurysmal in
adults.4 The normal pressure of the portal venous system is
5 to 10 mm Hg and maintains the liver blood flow at
approximately 1 L/min.6
The etiology and pathogenesis of PVAs remains con-
troversial. Two current theories exist: The first considers
congenital factors with the incomplete regression of the
right vitelline vein or an inherent weakness in the venous
wall resulting in saccular aneurysms, which is supported by
a report of the in utero diagnosis of portal PVA by ultra-
sound imaging. The second theory favors acquired factors,
portal hypertension, and decompensation of vein wall
strength resulting in more fusiform aneurysms.4 Portal
hypertension has been reported in about 30% and liver
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findings support the hypothesis that portal hypertension is
contributory but not essential for the development of
PVA.2,7
Saccular extrahepatic PVAs are more common than the
fusiform type. These aneurysms are located most com-
monly at the main portal vein (26.2%), followed by the
confluence of the superior mesenteric vein and splenic veins
(18.6%) and then the intrahepatic branches (17.1%). There
is no gender preponderance, aneurysm diameters ranged
from 2.0 to 8.0 cm, and they have been identified in all age
groups (range, 0-87 years), with a median age of 52
years.2,8
Differing from arterial aneurysms, physical examination
is insufficient to make the diagnosis, and there are no
specific laboratory findings. Currently, most patients are
diagnosed incidentally while undergoing imaging for other
abdominal processes. The prevalence of PVA is 0.6/1000
on ultrasound imaging and 4.3/1000 on multidetector
Fig 1. Coronal and axial views taken in January 2007
aneurysm, with no mural thrombus or splenomegaly.
Fig 2. Coronal and axial views taken in June 2009 show
of the aneurysm.CT scanning.7 Ultrasound imaging, CT, and magneticresonance imaging can also be used for surveillance or
follow-up after treatment. These imaging modalities are
readily available today and have made splenoportography
nearly obsolete.
Most patients with PVA complain of mild nonspecific
abdominal pain (44.7%), others reported symptoms that
include jaundice and gastrointestinal bleeding. Reported
complications include rupture, thrombosis, mass effect on
the bile duct, duodenum or stomach, and inferior vena
cava.2,8 Complete thrombosis has occurred in about 14% of
reported cases, resulting in two deaths, whereas rupture was
uniformly fatal in the two reported patients. Two patients
with 2-cm splenic vein aneurysm rupture have also been
reported, one in the postpartum period.2
There is no consensus on the use of prophylactic anti-
platelet or anticoagulation medications, regardless of the
size of the PVA. Most authors advocate serial imaging for
patients with asymptomatic small PVAs,7 while patients
with thrombus within the PVA are usually treated with
the large, 6-cm saccular, extrahepatic, main portal vein
extrahepatic main portal vein, with complete regressionshowthesurgery or lysis. There is a general tendency for symp-
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to undergo surgical intervention. The natural history of
extra hepatic PVAs is not well documented, and there is
no general consensus on the treatment of asymptomatic
PVAs.
Two surgical reports recommend prophylactic surgery
in low-risk patients to prevent aneurysm-related complica-
tions; however, they cautioned against surgery, especially in
patients with portal hypertension and cirrhosis, with a
reported mortality of 40% in this patient group.3,8 Current
surgical therapies have included aneurysmectomy with al-
lograft replacement, aneurysmorrhaphy alone, liver trans-
plantation when coexisting malignancy exists, and throm-
bectomy and aneurysmorrhaphy. In patients who have
portal hypertension, shunt procedures combined with sple-
nectomy have been used to decompress the portal venous
system.3,8 Transhepatic thrombectomy and thrombolysis
have also been used in patients with thrombosed aneu-
rysms.7
Ozbek et al9 monitored five patients with serial ultra-
sound scans and found no enlargement over 2 years. They
suggested that in the absence of cirrhosis and portal hyper-
tension, asymptomatic aneurysms can be managed conser-
vatively.9 A review of follow-up of 53 patients during a
mean period of 21 months showed that in 50 (94%) pa-
tients, the aneurysm remained stable with no complica-
tions, in 2 patients the aneurysm increased in size, and 1
had cavernous transformation.2 Cho et al,8 in their series of
6 patients with PVA, observed 2 patients (with 12 and 56
months follow-up) in 1 patient the PVA decreased in size.
We cannot explain why the PVA in our patient under-
went a rather rapid, complete regression. Although the
starting of a statin medication 2 years before the regression
was observedmay be totally coincidental, it is an interesting
observation. To date, we have the longest follow-up with
serial observation in an asymptomatic patient without por-tal hypertension, and to our knowledge, this is the only
reported case with complete spontaneous regression of the
PVA.
CONCLUSIONS
Although we cannot draw strong conclusions from this
case, we think that observation with periodic imaging of
asymptomatic PVAs in medically high-risk patients, espe-
cially in those without portal hypertension, may be reason-
able until the natural history of these aneurysms is better
understood.
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